Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ALT
ALTIMMUNE, INC.
NASDAQ
$3.11
▲ UP 5.42% (0.16)

KEY STATISTICS

Market Cap$604.81 M
52w High$6.44
52w Low$2.56
Dividend Yield1310.82%
FrequencyMonthly
P/E-3.99
Volume6.16M
Shares Out.194.47M

COMPANY

LEADERSHIP

Jerome Benedict Durso
CHIEF EXECUTIVE
Jerome Benedict Durso

COMPENSATION 2026

Salary$658,694
Stock Awards$1,153,600
Incentive Plan Pay$357,753
All Other Comp.$1,043,376
Total$8,026,590

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 26, 2017
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
57

PRICE TARGET

Target High$10.00
Target Low$2.50
Target Median$6.25
Target Consensus$6.25

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$1.75K
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2018-09-14Reverse1:30
2017-05-05Forward10:1

PRICE

$3.11 ▲ UP 5.42% (+$0.16)
OVERLAYS
$3.00$3.10$3.209:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM3.11

About Altimmune, Inc.

https://altimmune.com ↗

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing treatments for obesity, liver diseases, and hepatitis B, with lead candidates including pemvidutide and HepTcell.

INDUSTRY

Biotechnology

A PRODUCT ALTIMMUNE, INC. IS KNOWN FOR

Pemvidutide
Pemvidutide

Pemvidutide, Altimmune's lead investigational peptide-based GLP-1/glucagon dual receptor agonist, is in late-stage trials for MASH and obesity, and is also being studied for alcohol use disorder and alcohol-associated liver disease.

COMPETITORS

COMPETITOR
GPCR COMPARE
LLY COMPARE
MDGL COMPARE
NVO COMPARE
VKTX COMPARE

Revenue by Products

IconPRODUCTQ1-2021Q2-2021Q3-2021Q4-2021
Grant$200K $100K ▼$100K $3.3M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
88
LISTED HERE
16
RANKED BY POSITION SIZE
XBI
0.22% · 8.5M
VTS.AX
0.00% · 5.7M
XSU.TO
0.02% · 5.1M
FESM
0.06% · 1.4M
LABU
0.15% · 337.4K
SBIO
0.30% · 229.0K
DFMC
0.01% · 210.7K
PRFZ
0.02% · 183.4K
XRS2.DE
0.02% · 172.5K
BBC
0.69% · 119.1K
RSSL
0.02% · 94.4K
SILX
0.30% · 15.8K
AVSC
0.00% · 13.3K
URTY
0.01% · 8.1K
PWS
0.04% · 3.8K
RESM
0.02% · 360

INSTITUTIONAL OWNERSHIP

SHARES OWNED
55.69%
HOLDERS
293
TOP 12 OF 293 · RANKED BY POSITION SIZE
Blackrock, Inc.
20.4M sh · $61.97M
Deep Track Capital, LP
19.3M sh · $58.52M
State Street Corp
12.1M sh · $36.78M
Tcg Crossover Management, LLC
10.0M sh · $30.4M
Vanguard Group Inc
9.5M sh · $34.26M
Marshall Wace, Llp
6.8M sh · $20.8M
Viking Global Investors LP
6.7M sh · $20.37M
Ra Capital Management, L.P.
6.5M sh · $19.76M
Blackrock Inc.
5.3M sh · $35.39M
Geode Capital Management, LLC
5.0M sh · $15.24M
Woodline Partners LP
3.4M sh · $10.34M
Millennium Management LLC
3.3M sh · $10.06M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Durso Jerome Benedict
Purchase · 15.0K shares
2026-08-13
★
OFFICER: CHIEF FINANCIAL OFFICER
WEAVER GREGORY L
Purchase · 1.8K shares
2026-07-31
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Roberts M Scot
Purchase · 875 shares
2026-07-31
★
DIRECTOR
Jorkasky Diane
Purchase · 48.8K shares
2026-05-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
MARKET OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Citizens MARKET OUTPERFORM B. Riley Securities BUY

SECTORS PEERS

PEERPRICE
LBRX$47.62COMPARE
ANRO$34.28COMPARE
ANNX$5.07COMPARE
AURA$7.80COMPARE
LRMR$4.18COMPARE
DBVT$14.55COMPARE
ACIU$2.90COMPARE
AMRN$14.09COMPARE